The annualized US Lovenox market is around $600M, IMO. In 3Q12, SNY’s branded sales of $71M plus NVS’ sales of $34M came to $105M, and it’s reasonable to assume that SNY’s AG plus Amphastar’s hospital sales plus WPI’s retail sales generated another $45M or so. So that’s $150M in all for the quarter.